Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
G-23, monoclonal
Application:
FACS
Citations:
62
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
G-23, monoclonal
form
buffered aqueous solution
species reactivity
human
concentration
1 mg/mL
technique(s)
flow cytometry: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... IFNG(3458)
General description
The antibody G-23 reacts with IFN-gamma, a 20-25 kDa cytokine produced by activated Th1 cells and NK cells.
Immunogen
Recombinant human IFN-gamma (aa 22-166 representing mature IFN-gamma)
Application
The reagent is designed for Flow Cytometry analysis. Suggested working dilution is 2-4 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
常规特殊物品
低风险生物材料
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Alanna M Klose et al.
Sensors (Basel, Switzerland), 20(20) (2020-10-15)
While label-free multiplex sensor technology enables "mixing and matching" of different capture molecules in principle, in practice this has been rarely (if ever) demonstrated. To fill this gap, we developed protocols for the preparation of mixed aptamer-protein arrays on the
Adele M Barr et al.
Cancer immunology, immunotherapy : CII, 69(10), 1959-1972 (2020-05-11)
Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to
David Laurin et al.
Journal of biomedicine & biotechnology, 2010, 234540-234540 (2010-07-10)
Adoptive transfer of specific cytotoxic T lymphocytes (CTL) and Cytokine Induced Killer Cells (CIK) following genetic engineering of T-cell receptor zeta hold promising perspective in immunotherapy. In the present work we focused on the mechanisms of anti-tumor action of effectors
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SAB4700340-100UG | 04061829672157 |